Back

Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program

26 August 2023 (17:15 - 17:50)
Organised by: Logo
Congress Presentation Part of: Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Igor Diemberger

Institute of Cardiology University of Bologna, Bologna (Italy)

5 More presentations in this session

Presentation thumbnail
A genetic polymorphism on chromosome 4q25 (rs17570669_T) may predict atrial fibrillation recurrence after successful electrical cardioversion
Professor T. Ulus (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study
Associate Professor M. Wybraniec (Katowice, PL)
Abstract Slides Video
Presentation thumbnail
Intravenous infusion of potassium/magnesium solution for the treatment of postoperative atrial fibrillation after coronary artery bypass graft: a randomized, double-blinded, parallel controlled trial
Doctor F. Masoudkabir (Tehran, IR)
Abstract Slides Video
Presentation thumbnail
Efficacy of bepridil as a periprocedural support drug in atrial fibrillation patients with left ventricular systolic dysfunction undergoing catheter ablation
Mr K. Okabe (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Development of an in vitro platform for transesophageal echocardiographic and color Doppler hemodynamic assessments of left atrial appendage occlusion devices
Mr Z. Zhong (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation

The Event

Event poster

ESC Congress 2023

26 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors for non-persistence to edoxaban in Asian patients with atrial fibrillation: 2-year follow-up data from the ETNA-AF programme
thumbnail
Congress Presentation
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study
thumbnail
Congress Presentation
Association of diabetes mellitus status and clinical outcomes of edoxaban in patients with atrial fibrillation: a sub-analysis from the ETNA-AF Asian registry

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources